Analyst firms · UBS · OSCR
UBS OSCR price target and rating history
Oscar Health Inc. (OSCR) · Health Care
UBS rates Oscar Health Inc. (OSCR) Neutral with a $17 price target, as of its latest action on Jan 9, 2026. It has published 3 rating actions on OSCR since October 2024, including 1 upgrade and 1 downgrade. Across 7 firms with a OSCR price target in the last 12 months, the median target is $18. UBS's $17 is 6% below that.
- Current rating
- Neutral
- Price target
- $17
- Median target, all firms
- $18
- Actions on OSCR
- 3
UBS price target on OSCR
Every UBS rating on OSCR
- Jan 9, 2026
- Jul 15, 2025
- Oct 7, 2024
How other firms rate OSCR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $35 | Jun 10, 2026 |
| Wells Fargo | Equal Weight | $20 | Jun 4, 2026 |
| Wolfe Research | Peer Perform | May 6, 2026 | |
| Jefferies | Hold | $16 | Apr 20, 2026 |
| Raymond James | Outperform | $18 | Feb 12, 2026 |
| UBS | Neutral | $17 | Jan 9, 2026 |
| Stephens | Equal-Weight | $17 | Dec 11, 2025 |
| Piper Sandler | Overweight | $25 | Nov 26, 2025 |
Questions about UBS and OSCR
- What is UBS's price target for OSCR?
- UBS's latest stated price target for Oscar Health Inc. (OSCR) is $17, from its action on Jan 9, 2026.
- What is UBS's rating on OSCR?
- UBS rates OSCR Neutral, a neutral rating, as of Jan 9, 2026.
- When did UBS last change its view on OSCR?
- On Jan 9, 2026, UBS upgrades to Neutral from Sell, price target $17.
- How does UBS's OSCR target compare with other analysts?
- Across 7 firms with a OSCR price target in the last 12 months, the median target is $18. UBS's $17 is 6% below that.
More OSCR rating histories
All UBS ratingsOSCR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.